Capricor Therapeutics (NASDAQ:CAPR) Given "Buy" Rating at HC Wainwright

Key Points

• HC Wainwright has restated a "buy" rating for Capricor Therapeutics (NASDAQ:CAPR) with a target price of $24.00, indicating a potential upside of 280.35% from the current trading price.
• Despite the positive outlook from HC Wainwright, other analysts have varied opinions, with Roth Capital reducing their price target from $31.00 to $12.00 while maintaining a "buy" rating.
• Capricor Therapeutics recently reported a loss per share of ($0.57) for the quarter, missing analysts' estimates and highlighting ongoing financial challenges for the company.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $24.00 target price on the biotechnology company's stock. HC Wainwright's price target suggests a potential upside of 280.35% from the stock's previous close.

Several other analysts have also weighed in on CAPR. Roth Capital dropped their price objective on shares of Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating for the company in a report on Monday, July 14th. Cantor Fitzgerald restated an "overweight" rating and set a $30.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen downgraded Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Jones Trading reduced their price objective on Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating on the stock in a research note on Wednesday, June 25th. Finally, Oppenheimer decreased their target price on Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating on the stock in a report on Monday, June 23rd. One analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. Based on data from MarketBeat, Capricor Therapeutics currently has an average rating of "Buy" and an average target price of $22.56.

Capricor Therapeutics Trading Down 0.3%

CAPR traded down $0.02 on Thursday, hitting $6.31. 215,572 shares of the stock traded hands, compared to its average volume of 1,943,283. Capricor Therapeutics has a 52 week low of $4.05 and a 52 week high of $23.40. The firm has a market capitalization of $288.49 million, a PE ratio of -3.83 and a beta of 0.73. The business has a fifty day moving average price of $7.54 and a two-hundred day moving average price of $9.96.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%. On average, equities research analysts forecast that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CAPR. Tower Research Capital LLC TRC lifted its stake in Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company's stock valued at $67,000 after buying an additional 4,976 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Capricor Therapeutics by 2,342.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 36,398 shares of the biotechnology company's stock valued at $361,000 after acquiring an additional 34,908 shares during the last quarter. Jump Financial LLC raised its position in shares of Capricor Therapeutics by 42.6% in the 2nd quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company's stock valued at $2,309,000 after acquiring an additional 69,515 shares during the period. Marshall Wace LLP acquired a new stake in shares of Capricor Therapeutics in the 2nd quarter valued at approximately $796,000. Finally, Rhumbline Advisers boosted its stake in Capricor Therapeutics by 7.3% during the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company's stock worth $531,000 after acquiring an additional 3,636 shares during the last quarter. 21.68% of the stock is owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.